LOS ANGELES (Reuters) - Pfizer Inc. said on Tuesday pivotal-stage trials found that adding its experimental HIV drug maraviroc to a regimen of the best-available drugs resulted in twice as many patients achieving suppression of the virus.
LOS ANGELES (Reuters) - Pfizer Inc. said on Tuesday pivotal-stage trials found that adding its experimental HIV drug maraviroc to a regimen of the best-available drugs resulted in twice as many patients achieving suppression of the virus.
